NCT01226615View on ClinicalTrials.gov

Assessment of the Effects of Chondroitin Sulphate in Patients With Knee Osteoarthritis With Functional Magnetic Resonance Imaging (fMRI)

PHASE4UnknownINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

October 31, 2011

Study Completion Date

December 31, 2012

Conditions
Knee Osteoarthritis
Interventions
DRUG

Chondroitin sulphate (Condrosan®)

800mg (two capsules of 400mg each) taken once a day for four months

DRUG

Placebo

Two placebo capsules taken once a day for four months.

Trial Locations (1)

Unknown

Hospital del Mar, Barcelona

Sponsors

Lead Sponsor

Bioiberica
All Listed Sponsors
lead

Bioiberica

INDUSTRY

NCT01226615 - Assessment of the Effects of Chondroitin Sulphate in Patients With Knee Osteoarthritis With Functional Magnetic Resonance Imaging (fMRI) | Biotech Hunter | Biotech Hunter